
Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: ...
Introduction Ovarian cancer patients face a high burden of chronic and metabolic diseases, such as hypertension and dyslipidemia, the prevalence of which can be as high as 50%–70%.1 Over 75% of ovarian cancer patients are of middle or older age, …